Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan:9:e2200305.
doi: 10.1200/GO.22.00305.

Cancer Survivorship in the Indo-Pacific: Priorities for Progress

Affiliations
Review

Cancer Survivorship in the Indo-Pacific: Priorities for Progress

Bogda Koczwara et al. JCO Glob Oncol. 2023 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Bogda Koczwara

Employment: Australian Radiology Clinics

Alexandre Chan

Consulting or Advisory Role: Blueprint Medicines, Lilly, Hengrui Medicine

Carolyn Taylor

Travel, Accommodations, Expenses: Novartis, Pfizer

Other Relationship: Pfizer

Nirmala Bhoo‐Pathy

Honoraria: Roche, Novartis

Speakers' Bureau: Roche, Novartis

Research Funding: Pfizer, Novartis, Zuellig Pharma

Bishal Gyawali

This author is a member of the JCO Global Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.

Consulting or Advisory Role: Vivio Health

C.S. Pramesh

This author is a member of the JCO Global Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.

Stock and Other Ownership Interests: Aurobindo

Miyako Takahashi

Honoraria: Takeda, Chugai Pharma, Pfizer, AstraZeneca Japan, Kyowa Kirin International, Shionogi

Yu Ke

Employment: GlaxoSmithKline

No other potential conflicts of interest were reported.

Figures

FIG 1
FIG 1
The inter-relationship between care delivery, data monitoring, and research in cancer survivorship. PRO, patient reported outcomes.

Comment in

Similar articles

Cited by

References

    1. Global Burden of Disease 2019 Cancer Collaboration; Kocarnik JM, Compton K, et al. : Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: A systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol 8;420-444, 2022 - PMC - PubMed
    1. Roser M, Ritchie H: Cancer. 2015. https://ourworldindata.org/cancer
    1. Medcalf R: Reimagining Asia: From Asia-Pacific to Indo-Pacific, in Rozman G, Liow J (eds): International Relations and Asia’s Southern Tier. Asan-Palgrave Macmillan Series. Singapore, Springer, 2018
    1. Ferlay J, Laversanne M, Ervik M, et al. : Global Cancer Observatory: Cancer Tomorrow. Lyon, France: International Agency for Research on Cancer, 2020. https://gco.iarc.fr/tomorrow
    1. National Coalition for Cancer Survivorship. https://canceradvocacy.org/about/our-mission/

Publication types